PFE Mar 2025 40.000 call
| Previous close | 0.1700 |
| Open | 0.1500 |
| Bid | 0.1400 |
| Ask | 0.1700 |
| Strike | 40.00 |
| Expiry date | 2025-03-21 |
| Day's range | 0.1500 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.71k |
Investor's Business DailyA Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed
Stock market investors brace for a big week of earnings and econ as Apple, Amazon, Big Pharma and The Fed all line up to deliver news.
BenzingaFDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves
Investor's Business DailyPfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
